A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01565655 |
|
Recruitment Status :
Completed
First Posted : March 29, 2012
Last Update Posted : June 4, 2019
|
Sponsor:
Astellas Pharma Global Development, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis (RA) subjects
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Arthritis, Rheumatoid | Drug: peficitinib Drug: Placebo | Phase 2 |
Subjects will take ASP015K or matching placebo orally with food for 12 weeks after randomization. Potential subjects who have previously used disease-modifying antirheumatic drugs (DMARDs) and/or biologic agents may be eligible to participate after completing a washout period. Subjects who complete the 12-week dosing period in this study may be eligible to participate in a long-term, open-label Extension Study.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 289 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Patients |
| Actual Study Start Date : | June 19, 2012 |
| Actual Primary Completion Date : | December 2, 2013 |
| Actual Study Completion Date : | December 2, 2013 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Rheumatoid arthritis
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ASP015K lowest dose
ASP015K lowest dose once daily
|
Drug: peficitinib
oral
Other Name: ASP015K |
|
Experimental: ASP015K low dose
ASP015K low dose once daily
|
Drug: peficitinib
oral
Other Name: ASP015K |
|
Experimental: ASP015K medium dose
ASP015K medium dose once daily
|
Drug: peficitinib
oral
Other Name: ASP015K |
|
Experimental: ASP015K high dose
ASP015K high dose once daily
|
Drug: peficitinib
oral
Other Name: ASP015K |
|
Placebo Comparator: Placebo
Matching placebo once daily
|
Drug: Placebo
oral |
Primary Outcome Measures :
- Percentage of subjects achieving American College of Rheumatology Criteria 20 (ACR 20) response [ Time Frame: Week 12 ]
- Trough plasma concentration of ASP015K and metabolite(s) [ Time Frame: up to Week 12 (6 time points) ]
Secondary Outcome Measures :
- Percentage of subjects achieving ACR 50 response [ Time Frame: Week 12 ]
- Percentage of subjects achieving ACR 70 response [ Time Frame: Week 12 ]
- Change from baseline in Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP) [ Time Frame: Baseline and Week 12 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- ≥ 6 tender/painful joints; ≥ 6 swollen joints
- C-Reactive Protein (CRP) of ≥ 0.8 mg/dL or Erythrocyte Sedimentation Rate (ESR) of ≥ 28 mm/hr
- Subject meets the ACR 1991 Revised Criteria for Global Functional Status in RA Class I, II or III at Screening and Baseline
- Use of non-steroidal anti-inflammatory drugs [NSAIDs], cyclooxygenase-2 (COX-2) inhibitors, or oral corticosteroids for the treatment of RA must be stable for at least 28 days prior to start of the study
- Male and female subjects must be willing to comply with contraception requirements as well as restrictions regarding egg and sperm donation
- Female subject must not be breastfeeding at Screening or during the study period, and for 60 days after the final study drug administration
- Subject agrees not to participate in another interventional study while on treatment
Exclusion Criteria:
- Positive Mycobacterium tuberculosis (TB) test within 90 days of Screening
- Abnormal chest x-ray indicative of an acute or chronic infectious process or malignancy
- Receipt of live or live attenuated virus vaccination within 30 days prior to the first dose of study drug
- Known history of positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody or history of a positive test for human immunodeficiency virus (HIV) infection
- History of any other autoimmune rheumatic disease, other than Sjogren's syndrome
- Previous history of clinically significant infections or illness (requiring hospitalization or requiring parenteral therapy) within 90 days of the Baseline visit, or a history of any illness that would preclude participation in the study
- History of any malignancy, except for successfully treated basal or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix.
- Does not meet specified washout criteria for the following RA medications: gold, azathioprine, minocycline, penicillamine, etanercept, certolizumab, adalimumab, golimumab, infliximab, cyclophosphamide, and leflunomide
- Previous intolerance to Janus kinase (JAK) inhibitors
- Receipt of intra-articular or parenteral corticosteroid within 28 days prior to the first dose of study drug or is currently taking > 30 mg oral morphine (or narcotic equivalent) per day
- Receipt of plasma exchange therapy within 60 days prior to the start of study drug
- Receipt of any investigational agent within 30 days or 5 half-lives, whichever is longer, prior to first dose of study drug
- Receipt of medications that are CYP3A substrates with narrow therapeutic range within 14 days prior to first dose of study drug
- History of heart failure, defined as New York Heart Association (NYHA) grade 3 or greater
- History of long QT syndrome or prolonged QT interval
- Any ongoing severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological, or infectious disease, or any ongoing illness which would make the subject unsuitable for the study
- Subject has any condition possibly affecting oral absorption (e.g., gastrectomy, other malabsorption syndromes, or clinically significant diabetic gastroenteropathy)
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01565655
Locations
Show 38 study locations
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Investigators
| Study Director: | Senior Medical Director | Astellas Pharma Global Development |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Astellas Pharma Global Development, Inc. |
| ClinicalTrials.gov Identifier: | NCT01565655 |
| Other Study ID Numbers: |
015K-CL-RA22 2011-006020-20 ( EudraCT Number ) |
| First Posted: | March 29, 2012 Key Record Dates |
| Last Update Posted: | June 4, 2019 |
| Last Verified: | May 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) |
| Time Frame: | Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data. |
| Access Criteria: | Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement. |
| URL: | https://www.clinicalstudydatarequest.com/ |
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
|
Rheumatoid Arthritis ASP015K |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases |
Immune System Diseases Peficitinib Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |